Effect of dystonia and botulinum toxin treatment on health‐related quality of life

1998 ◽  
Vol 13 (6) ◽  
pp. 941-946 ◽  
Author(s):  
Claire M. Gudex ◽  
Maurice R. Hawthorne ◽  
Anthony G. Butler ◽  
Philip Duffey
Author(s):  
Alok Verma ◽  
Pavan Singh ◽  
Saurabh Agarwal ◽  
Babita Gupta

Background: There is paucity of literature regarding health related quality of life (HRQoL) in Meige’s syndrome (MS) especially from India. This study assessed HRQoL in its global and disease specific aspect by previously validated instruments in patients with Meige’s syndrome.Methods: The study was performed in AIIMS, New Delhi. Subjects with Meige’s syndrome as well as age and gender matched healthy controls were enrolled from Movement Disorder and botulinum toxin clinic, Department of Neurology, AIIMS, New Delhi. Uneducated patient, those could not read questionnaires and cases who had received botulinum toxin within 6 months were excluded from the study.Results: A 14 pts of Meige’s syndrome were enrolled and 14 age matched controls were taken. All the pts of Meige’s syndrome scored worse in SF-36 as compared to controls in areas of role physical (p =0.002), bodily pain (p = 0.001), general health (p = <0.001), social functioning (p = 0.05) and role emotion (p = <0.001). 50% of patients with Meige’s syndrome had depression out of whom 21.4 % had moderate depression. Patients with Meige’s syndrome had significantly impaired scores in 10 of the 12 subscales which was profound in areas of ocular pain, near activities, distance activities, social functioning, role difficulties, dependency, driving, compared to borderline impairment in general vision, mental health, color vision.Conclusions: This study clearly demonstrated that pts with Meige’s syndrome, suffered from significant impairment in HRQoL as compared to controls. Higher proportion of patients with Meige’s syndrome suffered from moderate depression compared to their control. Pts with Meige’s syndrome had severe impairment of vision related quality of life. 


Toxins ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 292
Author(s):  
Lorenzo Pietro Roncoroni ◽  
Daniel Weiss ◽  
Leonhard Hieber ◽  
Justine Sturm ◽  
Axel Börtlein ◽  
...  

Objective: The effects of botulinum toxin injections (BoNT) on health-related quality of life along the complex spectrum of spasticity needs further characterization to guide practitioners in a real-life therapeutic environment. Methods: In this study, we analyzed 50 consecutive and unselected patients with spasticity before and four weeks after re-injection of botulinum toxin. Health-related quality of life in terms of the EuroQol (EQ) as well as further motor and non-motor characteristics were assessed. Results: BoNT improved the EQ visual analog scale (EQ VAS). In addition, state of health and pain maxima improved. The EQ VAS improvement correlated with pre-injection characteristics of the EQ VAS and life satisfaction in the “movement disorders” domain. Conclusion: EQ VAS is sensitive for monitoring HR-QoL outcomes in an unselected real life observational cohort. This study may inform future studies intended to validate prediction variables that could inform on HR-QoL effects of BoNT treatment in spasticity.


2018 ◽  
Vol 5 (4) ◽  
pp. 798
Author(s):  
Alok Verma ◽  
Babita Gupta ◽  
Saurabh Agarwal

Background: There is paucity of literature regarding health related quality of life in Spasmodic Dysphonia (SD) especially from India. This study assessed HRQoL in it’s global and disease specific aspect by previously validated instruments in patients with SD.Methods: The study was performed in AIIMS, New Delhi. Subjects with SD as well as age and gender matched healthy controls were enrolled from Movement Disorder and botulinum toxin clinic, Department of Neurology, AIIMS, New Delhi. Uneducated patient, those could not read questionnaires & cases who had received botulinum toxin within 6 months were excluded from the study. Each patient filled SF-36, BDI, VoiSS-30 and VPQ questionnaire.Results: 14 pts of Spasmodic Dysphonia (SD) were enrolled. Compared with controls SD patients suffered from statistically significant impaired global health related quality of life (SF36) in areas of role physical (p = 0.007), general health (p = 0.004), social functioning (p = 0.024), role emotion (p = 0.008) and mental health (p=0.039). Patients with SD scored much worse in BDI scale than their control group (12.57±8.0 vs. 4.71±5.0, p=0.005). 65% pt of SD had depression out of whom 14% had moderate depression. SD patient group showed statistically significant impaired scores in disease-specific QOL (VoISS) in 2 out of 3 subscales, impairment (p= <0.001) and emotional (p=<.001) but not in physical (p=0.44). Voice quality of patients with SD was severely affected compared to controls (mean 37± 8.0 vs. 12.9± 1.5).Conclusions: This study clearly demonstrated that patients with SD suffered from significant impairment in HRQoL as compared to controls. Higher proportion of patients with SD suffered from mild to moderate depression compared to their control. 


BMJ Open ◽  
2014 ◽  
Vol 4 (10) ◽  
pp. e005150 ◽  
Author(s):  
Margaret Mordin ◽  
Catherine Masaquel ◽  
Chandra Abbott ◽  
Catherine Copley-Merriman

ObjectiveTo describe the health-related quality of life (HRQOL) burden of cervical dystonia (CD) and report on the HRQOL and patient perception of treatment benefits of abobotulinumtoxinA (Dysport).DesignThe safety and efficacy of a single injection of abobotulinumtoxinA for CD treatment were evaluated in a previously reported international, multicenter, double-blind, randomised trial. HRQOL measures were assessed in the trial and have not been previously reported.SettingMovement disorder clinics in the USA and Russia.ParticipantsPatients had to have a diagnosis of CD with symptoms for at least 18 months, as well as a total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score of at least 30; a Severity domain score of at least 15; and a Disability domain score of at least 3. Key exclusion criteria included treatment with botulinum toxin type A (BoNT-A) or botulinum toxin type B (BoNT-B) within 16 weeks of enrolment.InterventionsPatients were randomised to receive either 500 U abobotulinumtoxinA (n=55) or placebo (n=61).Primary and secondary outcome measuresEfficacy assessments included TWSTRS total (primary end point) and subscale scores at weeks 0, 4, 8, 12; a pain visual analogue scale at weeks 0 and 4; and HRQOL assessed by the SF-36 Health Survey (SF-36; secondary end point) at weeks 0 and 8.ResultsPatients with CD reported significantly greater impairment for all SF-36 domains relative to US norms. Patients treated with abobotulinumtoxinA reported significantly greater improvements in Physical Functioning, Role Physical, Bodily Pain, General Health and Role Emotional domains than placebo patients (p≤0.03 for all). The TWSTRS was significantly correlated with Physical Functioning, Role Physical and Bodily Pain scores, for those on active treatment.ConclusionsCD has a marked impact on HRQOL. Treatment with a single abobotulinumtoxinA injection results in significant improvement in patients’ HRQOL.Trial registration numberThe trial is registered at ClinicalTrials.gov, numbers NCT00257660 and NCT00288509.


Sign in / Sign up

Export Citation Format

Share Document